Skip to content
10-K

Annual Report

INHIBIKASE THERAPEUTICS, INC. IKT

0001193125-26-126371

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 20, 2026 132.03M sh
Shares Diluted FY 2025 · Dec 31, 2025 98.31M sh
Shares Diluted FY 2025 · Dec 31, 2024 23.71M sh
Capex FY 2025 · Dec 31, 2025 $13.4K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$27.79M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$19.15M
Cash And Equivalents FY 2025 · Dec 31, 2025 $178.8M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $97.5M
Stockholders Equity FY 2025 · Dec 31, 2025 $172.9M
Stockholders Equity FY 2025 · Dec 31, 2024 $94.87M
Stockholders Equity FY 2025 · Dec 31, 2023 $10.98M
Current Liabilities FY 2025 · Dec 31, 2025 $8.3M
Current Liabilities FY 2025 · Dec 31, 2024 $3.73M
Total Liabilities FY 2025 · Dec 31, 2025 $8.3M
Total Liabilities FY 2025 · Dec 31, 2024 $3.73M
Current Assets FY 2025 · Dec 31, 2025 $180.11M
Current Assets FY 2025 · Dec 31, 2024 $98.45M
Total Assets FY 2025 · Dec 31, 2025 $181.2M
Total Assets FY 2025 · Dec 31, 2024 $98.6M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.49
Eps Diluted FY 2025 · Dec 31, 2024 −$1.16
Eps Basic FY 2025 · Dec 31, 2025 −$0.49
Eps Basic FY 2025 · Dec 31, 2024 −$1.16
Sga Expense FY 2025 · Dec 31, 2025 $23.56M
Sga Expense FY 2025 · Dec 31, 2024 $11.38M
Rd Expense FY 2025 · Dec 31, 2025 $29.79M
Rd Expense FY 2025 · Dec 31, 2024 $17.21M
Net Income FY 2025 · Dec 31, 2025 −$48.26M
Net Income FY 2025 · Dec 31, 2024 −$27.52M
Operating Income FY 2025 · Dec 31, 2025 −$51.97M
Operating Income FY 2025 · Dec 31, 2024 −$28.59M